Bifogade filer
Magle Chemoswed Holding AB enters into exclusive license agreement for amniotic stem cell technology
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Magle Chemoswed Holding AB (“Magle Chemoswed”) today announces that Magle Chemoswed Holding AB and its subsidiary Magle Biopharma AB (together, the “Licensors”) have entered into an exclusive license agreement (the “Agreement”) with Aktiebolaget Grundstenen 178422 which has applied for a name change to Alvion Bio AB (“Alvion Bio”), granting Alvion Bio exclusive worldwide rights to develop and commercialise the Group’s amniotic stem cell technology.
Alvion Bio has been established for the sole purpose of developing and commercialising the licensed technology and is owned by Justin Pierce, former Chief Executive Officer of Magle Group.
Under the Agreement, Alvion Bio will assume full responsibility for the continued development, regulatory advancement, and commercialisation of the licensed technology within the defined field.
The Agreement is not expected to have a material impact on Magle Chemoswed’ s financial results in 2026 but is expected to reduce operating costs by approximately SEK10 million and may generate future royalty revenue.
The licensed technology comprises intellectual property, know-how, cell lines, manufacturing processes, data, and related materials associated with amniotic stem cell–derived products. Alvion Bio has been established specifically to continue development activities and pursue regulatory approval and commercialisation of therapeutic products based on the licensed technology.
As part of the transaction:
- Alvion Bio receives an exclusive, worldwide licence to the technology and related intellectual property;
- As consideration for the licence, Magle Chemoswed AB and Magle Biopharma AB shall receive a royalty equal to four percent (4%) of all revenues generated from the commercialisation of the Licensed Technology and/or Licensed IPR by Alvion Bio, its Affiliates, and its Sublicensees. The obligation to pay royalties shall commence upon the first receipt of any Commercial Use Revenue by Alvion Bio, its Affiliates, or Sublicensees derived from the Licensed Technology and/or Licensed IPR. Royalties shall be payable on an ongoing basis for as long as Alvion Bio, its Affiliates, Sublicensees, or any successors or assigns continue to generate or receive Commercial Use Revenue from the Licensed Technology and/or Licensed IPR, and shall continue irrespective of whether any Licensed Patent has expired, lapsed, been abandoned, invalidated, or otherwise ceased to be in force.
- Alvion Bio assumes full operational, regulatory, development, and commercial responsibility and associated risks from the effective date; and
- Magle Group will provide limited transitional support during 2026 related to patent maintenance and transfer of documentation and materials.
“This agreement represents an important strategic milestone for Magle Group. It enables a structured exit from the amniotic stem cell field while preserving long-term value potential through royalties and participation in future commercial success. At the same time, it allows us to sharpen our focus on our core business and strategic priorities,” said Aaron Wong, interim CEO of Magle Chemoswed Holding AB.
The Agreement was entered into on 28 February 2026, and becomes effective immediately.